1 |
Kousidou, O. C., Mitropoulou, T. N., Roussidis, A. E., Kletsas, D., Theocharis, A. D. and Karamanos, N. K. 2005. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int. J. Oncol. 26, 1101-1109.
|
2 |
Kupai, K., Szucs, G., Cseh, S., Hajdu, I., Csonka, C., Csont, T. and Ferdinandy, P. 2010. Matrix metalloproteinase activity assays: Importance of zymography. J. Pharmacol. Toxicol. Methods 61, 205-209.
DOI
|
3 |
Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
DOI
ScienceOn
|
4 |
Lukaszewicz-Zając, M., Mroczko, B. and Szmitkowski, M. 2011. Gastric cancer - The role of matrix metalloproteinases in tumor progression. Clin. Chim. Acta 412, 1725-1730.
DOI
|
5 |
Mignatti, P. and Rifkin, D. B. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-95.
|
6 |
Ouyang, G., Yao, L., Ruan, K., Song, G., Mao, Y. and Bao, S. 2009. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways. Cell Biol. Int. 33, 1237-1244.
DOI
|
7 |
Phromnoi, K., Yodkeeree, S., Anuchapreeda, S. and Limtrakul, P. 2009. Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta. Pharmacol. Sin. 30, 1169-1176.
DOI
|
8 |
Puli, S., Lai, J. C. and Bhushan, A. 2006. Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J. Neurooncol. 79, 135-142
DOI
|
9 |
Rowe, R. G. and Weiss, S. J. 2009. Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annu. Rev. Cell Dev. Biol. 25, 567-595.
DOI
|
10 |
Valachovicova, T., Slivova, V., Bergman, H., Shuherk, J. and Sliva, D. 2004. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-jB/AP-1-dependent and -independent pathways. Int. J. Oncol. 25, 1389-1395.
|
11 |
Visse, R. and Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839.
DOI
ScienceOn
|
12 |
Wang, X., Li, K. F., Adams, E. and Van Schepdael, A. 2011. Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Curr. Drug Metab. 12, 395-410.
DOI
|
13 |
Zhao, R., Xiang, N., Domann, F. E. and Zhong, W. 2009. Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutr. Cancer 61, 397-407.
DOI
|
14 |
Chernov, A. V. and Strongin, A. Y. 2011. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol. Concepts 2, 135-147.
|
15 |
Adlercruetz, C. H., Goldin, B. R., Gorbach, S. L., Hockerstedt, K. A. V., Watanabe, S., Hamalainen, E., Markkanen, M. H., Makela, T. H., Wahala, K. T., Hase, T. A. and Fotsis, T. 1996. Soybean phytoestrogen intake and cancer risk. J. Nutr. 125, 757S-770S.
|
16 |
Back, M., Ketelhuth, D. F. and Agewall, S. 2010. Matrix metalloproteinases in atherothrombosis. Prog. Cardiovasc. Dis. 52, 410-428.
DOI
|
17 |
Barnes, S. 1995. Effect of genistein on in vitro and in vivo models of cancer. J. Nutr. 125, 777S-783S.
|
18 |
Brooks, S. A., Lomax-Browne, H. J., Carter, T. M., Kinch, C. E. and Hall, D. M. 2010. Molecular interactions in cancer cell metastasis. Acta. Histochem. 112, 3-25.
DOI
|
19 |
Brownson, D. M., Azios, N. G., Fuqua, B. K., Dharmawardhane, S. F. and Mabry, T. J. 2002. Flavonoid effects relevant to cancer. J. Nutr. 132, 3482S-3489S.
|
20 |
Chetty, C., Rao, J. S. and Lakka, S. S. 2011. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics 12, 535-546.
DOI
|
21 |
Choi, Y. H., Lee, W. H., Park, K. Y, and Zhang, L. 2000. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn. J. Cancer Res. 91, 164-173.
DOI
|
22 |
Choi, Y. H., Zhang, L., Lee, W. H. and Park, K. Y. 1998. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int. J. Oncol. 13, 391-396.
|
23 |
Curry, T. E. Jr. and Osteen, K. G. 2001. Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol. Reprod. 64, 1285-1296.
DOI
|
24 |
Farina, H. G., Pomies, M., Alonso, D. F. and Gomez, D. E. 2006. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol. Rep. 16, 885-891.
|
25 |
Gruber, H. E., Ingram, J. A., Hoelscher, G. L., Zinchenko, N., Norton, H. J. and Hanley, E. N. Jr. 2009. Matrix metalloproteinase 28, a novel matrix metalloproteinase, is constitutively expressed in human intervertebral disc tissue and is present in matrix of more degenerated discs. Arthritis Res. Ther. 11, R184.
DOI
|
26 |
Ismail, I. A., Kang, K. S., Lee, H. A., Kim, J. W. and Sohn, Y. K. 2007. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. Eur. J. Pharmacol. 575, 12-20.
DOI
|
27 |
Hadler-Olsen, E., Fadnes, B., Sylte, I., Uhlin-Hansen, L. and Winberg, J. O. 2011. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 278, 28-45.
DOI
|
28 |
Huang, Q., Shen, H. M. and Ong, C. N. 2004. Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem. Pharmacol. 68, 361-371.
DOI
ScienceOn
|
29 |
Huang, X., Chen, S., Xu, L., Liu, Y., Deb, D. K., Platanias, L. C. and Bergan, R. C. 2005. Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65, 3470-3478.
|
30 |
Jiang, Y., Goldberg, I. D. and Shi, Y. E. 2002. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245-2252.
DOI
ScienceOn
|
31 |
Jin, C. Y., Park, C., Cheong, J., Choi, B. T., Lee, T. H., Lee, J. D., Lee, W. H., Kim, G. Y., Ryu, C. H. and Choi, Y. H. 2007. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett. 257, 56-64.
DOI
ScienceOn
|
32 |
Jin, C. Y., Park, C., Kim, G. Y., Lee, S. J., Kim, W. J. and Choi, Y. H. 2009. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem. Biol. Interact. 180, 143-150.
DOI
|
33 |
Jin, C. Y., Park, C., Moon, S. K., Kim, G. Y., Kwon, T. K., Lee, S. J., Kim, W. J. and Choi, Y. H. 2009. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage. Anticancer Drugs 20, 713-722.
DOI
|